Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Rhea-AI Summary
Clearmind Medicine (Nasdaq: CMND) reported that an independent Data and Safety Monitoring Board unanimously cleared progression of its FDA-approved Phase I/IIa trial of CMND-100 in Alcohol Use Disorder after a second interim review on March 4, 2026.
The DSMB found additional topline safety data from the second cohort — which used twice the dose of cohort one — acceptable and recommended moving to a third cohort dosed at 80 mg. The multinational, multicenter study continues to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy.
Positive
- DSMB unanimous recommendation to advance to third cohort
- Second cohort showed no serious adverse events and good tolerability
- Third cohort dose specified at 80 mg
- Multinational enrollment at Johns Hopkins, Tel Aviv Sourasky, Hadassah
Negative
- No efficacy or detailed quantitative outcomes disclosed from the second cohort
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner flagged only PALI up 2.37% with no news. Broader biotech peers show mixed moves (e.g., SILO +13.31%, SXTP -18.34%), suggesting company-specific rather than coordinated sector trading.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Clinical safety update | Positive | -8.2% | Reported additional positive safety data in second cohort and DSMB clearance. |
| Jan 14 | Cohort completion | Positive | +0.4% | Announced all six patients in second cohort completed treatment per protocol. |
| Dec 16 | Cohort enrollment done | Positive | -3.7% | Completed enrollment of six-patient second cohort across three clinical sites. |
| Dec 02 | Dosing milestone | Positive | -9.9% | First participant enrolled and dosed at Hadassah in multinational CMND-100 trial. |
| Dec 01 | Multiple trial milestones | Positive | -6.9% | Positive first-cohort data, DSMB go-ahead, and new elite site activation. |
Clinical trial updates for CMND-100 have generally been positive but historically coincided with negative average moves of -5.66%, indicating frequent divergence between upbeat data and price reaction.
Over recent months, Clearmind’s CMND-100 Alcohol Use Disorder program has advanced through enrollment, dosing, and repeated DSMB reviews. Prior updates highlighted positive safety, preliminary efficacy, and unanimous DSMB recommendations to continue. Despite these milestones and expansion across multinational sites, same-tag clinical trial news saw an average -5.66% one-day move, signaling that historically, the market often reacted cautiously to similar CMND-100 progress updates.
Historical Comparison
Past CMND-100 clinical-trial announcements (5 events) averaged a -5.66% one-day move, showing that upbeat safety and DSMB updates have often met cautious market responses.
Clinical-trial news shows a clear CMND-100 trajectory: initial positive cohort data and DSMB approvals, followed by expanded enrollment, dosing at additional multinational sites, completion of second-cohort treatment, and now DSMB-backed advancement to a higher-dose third cohort.
Market Pulse Summary
This announcement confirms that an independent DSMB reviewed additional CMND-100 data, found no serious adverse events, and endorsed advancing to a higher 80 mg third-cohort dose in the Phase I/IIa Alcohol Use Disorder trial. It reinforces a favorable safety and tolerability profile across six treated second-cohort participants. In context of multiple prior CMND-100 milestones, investors may watch for future readouts on pharmacokinetics, preliminary efficacy, and how ongoing regulatory filings and financing structures support continued trial execution.
Key Terms
data and safety monitoring board medical
phase i/iia medical
alcohol use disorder medical
serious adverse events medical
pharmacokinetics medical
multicenter study medical
AI-generated analysis. Not financial advice.
The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial
Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that its independent Data and Safety Monitoring Board (“DSMB”) has completed the second scheduled interim review of the Company’s ongoing FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary, non-hallucinogenic neuroplastogen, in the treatment of Alcohol Use Disorder (“AUD”). Based on the encouraging additional top-line data from the second cohort, which demonstrated a favorable safety profile, the DSMB recommended that the clinical trial continue.
These further safety data points, emerging following the successful completion of treatment of another six participants of the second cohort, previously announced January 14, 2026, continue to strengthen the encouraging safety and tolerability profile previously established in the first cohort.
The results of the second cohort, in which twice the dose was administered compared to a single dose in the first cohort, reinforce no serious adverse events and overall good tolerability, consistent with the favorable results reported from the first cohort, support the rapid progression enabled by the DSMB’s unanimous approval to advance for the third cohort, for which the dose is 80 mg per administration, which is double the dose administered in the second cohort.
The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The second cohort, conducted across leading sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, achieved full treatment completion shortly after DSMB clearance, underscoring continued confidence in CMND-100’s safety profile as a potential innovative therapy for AUD.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce about the Phase I/IIa trial on March 4, 2026?
What dose will Clearmind (CMND) use in the third cohort of the CMND-100 trial?
What safety findings did Clearmind (CMND) report for the second cohort?
Which sites participated in Clearmind's CMND-100 second cohort study?
Does the March 4, 2026 update include efficacy results for CMND-100 (CMND)?
